STROKE (H.C. DIENER, SECTION EDITOR)

Updates in the Treatment of Post-Stroke Pain

Alyson R. Plecash [1] · Amokrane Chebini [1] · Alvin Ip [2] · Joshua J. Lai [1] · Andrew A. Mattar [1] · Jason Randhawa [1] · Thalia S. Field [1,3]

Abstract

Purpose of Review To provide an overview of the current treatment strategies for common subtypes of post-stroke pain.
Recent Findings There is growing research interest in non-pharmacological treatment approaches for chronic pain, including neurostimulation as well as lifestyle and psychosocial interventions. Newer pharmacotherapy research includes cannabinoids and NMDA-receptor antagonists as well as bee venom. Persistent post-stroke headache is an increasingly appreciated entity, though the role of novel chronic migraine treatments for post-stroke headache is not known.
Summary Overall, most treatment approaches to post-stroke pain lack high-quality evidence. Stroke survivors are in need of effective treatments based on methodologically sound evidence. To address the interplay of clinical and psychosocial factors that contribute to post-stroke pain, it may be reasonable to adopt a multimodal treatment strategy incorporating both lifestyle interventions and conventional therapies.

Keywords Stroke · Pain · Therapy · Non-pharmacologic · Lifestyle · Headache · Spasticity

Introduction

Stroke is the commonest cause of adult-acquired disability and the second-leading cause of death worldwide [1]. Recent advances in the treatment of acute ischemic stroke, including mechanical thrombectomy and image-guided selection of candidates for reperfusion therapy, have led to lower rates of functional dependence and decreased post-stroke mortality [2, 3].

Despite improved rates of functional independence, even stroke survivors with "good" or "excellent" outcomes as per traditional clinical trial outcome measures such as the modified Rankin Scale continue to experience "invisible" complications, including post-stroke pain, mood issues, fatigue, and reduced quality of life [4]. These complications are frequent, affecting up to half of stroke survivors, and recognition and treatment of these issues may help to improve function and post-stroke quality of life.

Post-stroke pain in particular may affect up to 50% of stroke survivors, with the majority experiencing pain on a daily basis [4, 5]. Those developing a new chronic pain syndrome after stroke have a greater likelihood of functional dependence, cognitive decline, depression, and suicidality, with pain severity correlating with degree of cognitive impairment and depression [6–8].

There are multiple post-stroke pain syndromes that can occur alone or in combination, and mechanisms may include both neuropathic and nociceptive elements. A number of demographic and clinical characteristics are risk factors for post-stroke pain. Female sex is an independent risk factor for the development of a post-stroke pain syndrome [6]. Although older age at stroke onset is associated with the development of any pain syndrome, younger patients are at increased risk for central post-stroke pain in particular [6, 9]. Premorbid peripheral vascular disease and alcohol and statin use prior to stroke, as well as a history of depression, predict the likelihood for developing any post-stroke pain syndrome [4, 6]. Stroke-related factors associated with developing pain include ischemic stroke and thalamic or brainstem localization. Those who develop post-stroke spasticity, severe upper extremity

✉ Thalia S. Field
thalia.field@ubc.ca

1   Division of Neurology, Faculty of Medicine, University of British Columbia, S169-2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada

2   Division of Physical Medicine and Rehabilitation, University of British Columbia, Vancouver, BC, Canada

3   Vancouver Stroke Program, Vancouver Coastal Health, Vancouver, BC, Canada

weakness and sensory deficits are also at higher risk [4, 10]. While the role of psychosocial factors in the development and prognosis of post-stroke pain specifically is understudied, pre-stroke anxious personality traits and depressive symptoms are an overall predictor for chronic pain and post-stroke complications frequently co-occurring with pain, including depression, anxiety, and fatigue [11–13]. .Social supports are protective against chronic pain and predict post-stroke social participation [14–16]. (Fig. 1).

Early and effective treatment of chronic pain is associated with improved prognosis both with regards to pain control as well as quality of life. Approaches to the identification and assessment of post-stroke pain types have been addressed in previous reviews [4, 17•, 18–20]. Here, we provide an updated overview of pharmacological and non-pharmacological therapeutic approaches for common subtypes of post-stroke pain. Given the complex interrelation between medical and psychosocial aspects of post-stroke pain and other post-stroke complications, a multimodal strategy incorporating lifestyle-related interventions in addition to medical treatments may optimize prognosis with improved quality of life and social participation after stroke.

Lifestyle and Psychosocial Interventions for Post-Stroke Pain

Both single-strategy and multimodal lifestyle interventions related to exercise, mindfulness, diet, and social participation are active areas of study in stroke rehabilitation. However, post-stroke pain remains an under-researched outcome and further high-quality evidence, particularly for non-exercise interventions, is needed.


Fig. 1 Post-stroke pain continuum

The effects of exercise interventions specifically for post-stroke pain have not been studied extensively. However, exercise interventions in stroke survivors have shown to have a beneficial role in addressing challenges associated with pain after stroke, including mobility, fatigue, and self-efficacy [21, 22••]. In addition, exercise interventions provide opportunities for social participation and peer interactions, which are associated with improved self-management in chronic pain populations [23]. A qualitative instrumental case study design to evaluate a post-stroke peer support program found perceived benefits, including validation, hope and a reduced sense of isolation. This was true for both new stroke survivors and caregivers. Still, the authors concluded that further study was required to identify those most likely to benefit from individual as opposed to group programs, as well as to examine the durability of benefits over time [24]. To our knowledge, the role of online peer-support interventions has not been formally assessed.

Virtual reality (VR) and interactive video gaming have been studied for other forms of chronic pain, though evidence in support of their effectiveness in durable pain reduction is equivocal [25]. The role of VR and interactive gaming in stroke rehabilitation has been recently reviewed. While there is some evidence that these strategies may provide a benefit for upper limb function and activities of daily living over conventional rehabilitation, there was insufficient evidence to suggest a benefit in quality-of-life and pain was not studied as an outcome [26].

The effect of mindfulness on post-stroke rehabilitation outcomes was recently studied in a systematic review and meta-analysis. Pain was not specifically addressed, though the authors found a positive effect on sensorimotor outcomes [27]. A recent Cochrane review examining the specific benefits of yoga alone in chronic stroke cohorts found one of two included studies assessed pain, but found no benefit of an 8-week, twice-weekly intervention on the 3-item Pain-Enjoyment-General Activity (PEG) scale [28].

The overall evidence for post-stroke dietary interventions on clinical outcomes is scant. A subanalysis of the large randomized VITATOPS secondary prevention trial found a modest but significant effect on B-vitamin supplementation on post-stroke depression, though pain was not examined as an outcome [29].

Treatment Strategies for Specific Post-Stroke Pain Subtypes

Central Post-Stroke Pain (CPSP)

Central post-stroke pain broadly defines a chronic central pain disorder. The characteristics and patient descriptions of CPSP are variable, making it challenging to distinguish this entity

from other neuropathic pain conditions [10]. CPSP may be spontaneous (with constant and/or paroxysmal components) or can be evoked by nociceptive (hyperalgesia) or normioceptive (allodynia) stimuli. The reported prevalence of CPSP ranges from less than 1 to 35% of patients following stroke [30], and it is thought to account for roughly one-third of post-stroke pain [4]. Commonly, CPSP develops about 3 to 6 months after stroke; however, latencies ranging from within a week to several years following stroke are reported [30]. Possible mechanisms for this increasingly recognized, and perhaps heterogeneous, condition include central sensitization, alterations in spinothalamic function, disinhibition, and thalamic or other neuroanatomic changes [10].

Approach to Treatment: Pharmacologic

First-Line Therapies Treatment of CPSP is made challenging by the paucity of high-quality evidence to guide pharmacological management. A recent comprehensive systematic review on treatment of CPSP found low or very low-certainty evidence in favor of common treatment approaches recommended in international pain society guidelines, including tricyclic antidepressants and anticonvulsants [19].

Pharmacological approaches are extrapolated from other treatment models for neuropathic pain [19, 31]. Tricyclic antidepressants (e.g., nortriptyline and amitriptyline), serotonin and norepinephrine reuptake inhibitors (SNRI, e.g., duloxetine) or calcium channel $\alpha2\delta$ ligands (e.g., pregabalin and gabapentin) are recommended as first-line agents for central post-stroke pain [32–36], though one randomized trial of a 13-week intervention of pregabalin (150–600 mg/day) versus placebo in 219 participants found no difference in pain as measured by the Daily Pain Rating Scale [33]. First-line agents have not been compared head-to-head in individuals with CPSP. A network meta-analysis of treatment approaches for chronic neuropathic pain, however, is currently underway [37].

Second- and Third-Line Therapies Antiepileptics, including carbamazepine or lamotrigine, may be used as second-line agents [38, 39]. Lamotrigine has better evidence in CPSP specifically, with one small placebo-controlled double-cross-over trial of 30 patients finding a significant reduction in pain scores at 200 mg/day, but not at lower doses [40]. Neither carbemazepine nor levetiracetam were found to be effective in small randomized trials [41]. Evidence for third-line strategies, including ketamine [42], intravenous lidocaine infusions [43], or steroids [44, 45] in CPSP, is even more limited. These therapies are best provided by a dedicated pain specialist in collaboration with the treating neurologist in refractory cases.

Other Therapies and Opportunities for Future Research Clinicians are increasingly recognizing the utility of

medications with N-methyl D-aspartate (NMDA) receptor antagonist effects (including ketamine, amantadine, memantine, other anti-epileptic medications, dextromethorphan, and methadone) for neuropathic pain [46]. Traditional opioids are generally not recommended as long-term strategies to treat neuropathic pain, given the potential for misuse and other adverse effects [47]. However, tramadol, which also has SNRI properties, may be an effective adjunct in patients who do not respond to the first-line medications for CPSP [48]. The current evidence for methadone in CPSP is limited [49]. Over-the-counter analgesics (non-steroidal anti-inflammatories, acetaminophen) are unlikely to offer significant benefit for neuropathic pain, aside from their potential to act as opioid-sparing agents [50].

Cannabis-based medications, such as nabilone, [51, 52•] are increasingly being used for chronic neuropathic pain and as an opioid-sparing strategy. A popular active area of research, cannabinoids are also being investigated for treatment of spasticity (see "Spasticity" section below).

Various topical medications (amitriptyline, ketamine, lidocaine, and capsaicin) are used in localized neuropathic pain, but have not been studied specifically in CPSP [53]. Given the reduced side effect profile of topical as compared with systemic therapies, this is an area that would benefit from future study.

Ultimately, combination therapies often offer the most benefit in CPSP. Many of these medications have synergistic mechanisms of action that may allow lower doses of individual agents to be used, thus improving tolerability and efficacy. A trial-and-error approach is usually required to achieve adequate pain control with tolerable side effects.

Neurostimulation

Invasive and non-invasive neurostimulation is an area of ongoing study for post-stroke pain, though the quality of evidence to date is limited by heterogenous protocols, small studies, and lack of randomized study design in many cases. The mechanisms by which motor cortex stimulation may modulate pain pathways invoke network-level activation of inhibitory and facilitatory circuits between interconnected neural structures and pathways [54••].

Non-invasive Brain Stimulation Non-invasive brain stimulation strategies, such as repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), are active areas of research for functional recovery after stroke [55, 56]. Similar to pharmacologic-related knowledge gaps in treatment of CPSP, regimen-specific factors, including anatomical targets for stimulation and optimal frequency and duration of treatment, are areas of uncertainty in need of further research. A recent systematic review found very low-quality evidence in favor of single-dose high-

frequency, but not low-frequency, repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) for short-term effects on chronic pain of multiple etiologies [57].

Invasive Brain Stimulation There have been several non-randomized case series of electrical motor cortex stimulation including patients with CPSP [54••]. Two very small additional randomized studies for chronic neuropathic pain have compared on and off-stimulation conditions [58, 59]. A recent meta-analysis examining MCS for neuropathic pain of multiple etiologies found a pooled effect estimate of 35% improvement in visual analog pain scores in CPSP, though this was derived from only 58 individuals with CPSP overall across 12 studies [60].

A recent clinical trial examining deep brain stimulation (DBS) for CPSP used a randomized, placebo-controlled crossover design. Ten individuals with CPSP underwent bilateral DBS implantation targeting the ventral striatum and anterior limb of the internal capsule. There was no significant improvement in the primary endpoint, 6-month Pain Disability Index score. There were significant improvements in secondary outcomes related to the affective component of pain [61].

Spinal Cord Stimulation (SCS) fMRI and PET data have demonstrated that spinal cord stimulation (SCS) is associated with supraspinal functional alteration [54••]. Although SCS has documented evidence for treating particular types of peripheral neuropathic pain, there is no high-quality evidence supporting its effectiveness in CPSP [62]. The few uncontrolled published case series to date found success rates ranging from 7 to 75%, but possibly even higher rates of improvement with chronically implanted SCS [62–67]. Younger survivors and individuals with non-thalamic strokes were more likely to experience pain relief from SCS [62].

Other Therapies Caloric vestibular stimulation (CVS) was successful for treatment of CPSP in previous small case series [68–70]. A single-blind randomized pilot trial found that 3 weeks of twice-weekly bee venom acupuncture (BVA) point injections was associated with significant improvement in visual analogue pain scores as compared to saline injections in 16 patients with CPSP [71]. A recent Cochrane systematic review concluded that there is very low quality evidence supporting the use of transcutaneous electrical nerve stimulation (TENS) in patients with neuropathic pain, including CPSP [72].

Persistent Post-Stroke Headache

Persistent post-stroke headache has recently been defined as headache occurring around stroke onset that persists for more than three months [73]. Persistent post-stroke headache affects 23% of patients with risk factors including younger age, female sex, and presence of a pre-stroke primary headache disorder [74, 75]. In observational studies, persistent headache is especially prevalent in certain uncommon stroke mechanisms that typically present with acute headache, including cervical or intracranial artery dissection and cerebral venous sinus thrombosis [76, 77]. Spontaneous intracerebral hemorrhage, on the other hand, is associated with acute headache but has not been more strongly associated with persistent headache than atherosclerotic ischemic stroke [78]. Research to date on the prevalence of post-stroke headache includes methodogical challenges such as a lack of distinction between survivors of ischemic and hemorrhagic stroke, and further high-quality studies are needed.

Clinical Assessment and Diagnosis In assessing patients with post-stroke headache, secondary causes of persistent headache including recurrent stroke, hemorrhage, cerebral venous thrombosis, dural arteriovenous fistula, dissection, pseudoaneurysm, posterior reversible leukoencephalopathy, reversible cerebral vasoconstriction syndrome, giant cell arteritis, and intracranial infection should be considered in the appropriate clinical context [17•]. Those with unexpected worsening of focal deficits or new focal deficits and headache warrant repeat neuroimaging. Consideration of further work-up in patients without focal deficits but with other headache red flags including thunderclap, positional, unremitting, or otherwise atypical headache syndromes is also important.

Co-morbid post-stroke complications including obstructive sleep apnea, musculoskeletal issues such as hemiplegic shoulder pain, altered biomechanics, uncontrolled hypertension, obesity, and polypharmacy are common generators of or contributors to persistent headache that should be screened for during assessment [17•]. Post-stroke fatigue and mood disorders can contribute to persistent headache and may need to be addressed to achieve the most robust effects of treatment.

Approach to Treatment No evidence-based guidelines for the management of persistent post-stroke headache exist [17•]. It may be reasonable to treat according to the most similar primary headache phenomenology, although this approach lacks evidence. Non-pharmacologic strategies that may be effective in other post stroke pain syndromes may also be effective for headache. These include exercise, stretching, physiotherapy, cognitive behavioral therapy (CBT), and biofeedback. These may be particularly important for patients for whom headache is part of a more widespread post-stroke pain syndrome, and patients with co-morbid depression, anxiety, or fatigue. Medication-overuse headaches may complicate any primary or secondary headache disorder and should be screened for at

stroke follow-up. Important considerations for post-stroke patients include avoidance of vasoactive agents.

Opportunities for Future Research There is limited clinical experience in persistent post stroke headache with the new calcitonin gene-related peptide (CGRP) antagonists for migraine. Stroke or vascular disease is not contraindications to the use of these agents by the US Food and Drug Administration or Health Canada labelling. Further phase 4 post-market data may clarify whether these agents should be trialed in this patient population. Use of other migraine prophylactic agents such as beta blockers, calcium channel blockers, antiepileptics, antidepressants, and nutraceuticals for persistent post-stroke headache with migrainous features may be warranted but should take stroke mechanism and co-morbidities into account. There is a lack of evidence regarding strategies such as Onabotulinum toxin A or peripheral nerve blocks.

Spasticity

Spasticity is a velocity-dependent increase in muscle activation following a change in position/muscle length. Pathophysiologically, it is due to loss of descending inhibition on the spinal motor neurons from the injured upper motor neuron pathway. In the first month after stroke, 25–50% of patients are affected, with prevalence increasing over time [79–82]. .Risk factors for developing spasticity include stroke severity on baseline assessment, involvement of subcortical white matter tracts or the basal ganglia, and hemorrhagic stroke [82–84]. Spasticity is associated with post-stroke pain. A small prospective longitudinal study found that pain occurred in a majority of stroke survivors with spasticity (72%), but in only a minority of those without (1.5%) [79].

Approach to the Treatment of Post-Stroke Spasticity Traditionally, spasticity following stroke has been managed with splinting and range-of-motion exercises, despite challenges in tolerability/adherence, as well as an absence of evidence that these interventions are effective [85, 86]. To our knowledge, the effectiveness of splinting on reducing post-stroke pain has not been systematically studied.

Botulinum toxin injections have become a common treatment for spasticity. The effectiveness of botulinum in reducing spasticity in stroke patients is well-established [87, 88]. More recently, it has been shown that in addition to reducing spasticity, botulinum also reduces pain, and improves functionality at work for stroke patients [89].

Oral pharmacologic anti-spastic agents, including baclofen, tizanidine, diazepam, and dantrolene, are often used in spite of little evidence for their effectiveness in the post-stroke setting. A recent Cochrane review revealed insufficient evidence for spasticity reduction and functional improvement with the use of these agents in stroke populations [90]. Intrathecal and oral baclofen administration have been compared in a small randomized trial in a spinal cord injury population; the intrathecal group had reduced spasm frequency and severity, though there were no differences in pain or quality of life between groups [91]. One randomized trial comparing intrathecal baclofen to conventional medical management with oral antispastics was associated with improvement in both pain and spasticity in the baclofen group, though loss to follow-up and cross-over in a small trial make the conclusions more challenging to interpret [92].

Opportunities for Future Research There is increasing interest in the use of cannabinoids for treating spasticity. A recent meta-analysis [93] found efficacy for medical cannabinoids in the treatment of spasticity from multiple sclerosis (MS) and spinal cord injury, but not in stroke populations. The same review identified efficacy for the treatment of pain from multiple etiologies (neuropathic, MS-related, cancer and non-cancer, rheumatologic, etc.), but pain resulting from spasticity was not directly assessed. Recruitment is currently underway for a randomized trial comparing a cannabinoid (tetrahydrocannabinol and cannabidiol) oral spray to placebo for treatment of post-stroke spasticity, with pain as a secondary outcome [94].

Neuromodulatory transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are also being explored as therapies for spasticity. While there is some data for reduced post-stroke spasticity with TMS [95], the evidence to date does not support the routine use of non-invasive neuromodulation for spasticity [96].

Hemiplegic Shoulder Pain

Post-stroke shoulder pain is multifactorial, and both nociceptive and neuropathic mechanisms may contribute. It has been associated with shoulder soft tissue injury, as demonstrated by abnormal ultrasound findings of subacromial bursitis, bicipital tendinopathy, and rotator cuff pathologies commonly seen in patients with stroke [97, 98]. The altered movement patterns of patients at certain stages of motor recovery post-stroke have also been linked to shoulder pain, specifically glenohumeral subluxation in the acute phase and spasticity and adhesive capsulitis in the chronic phase [99, 100]. There is also mounting evidence for neuropathic pain mechanisms in chronic hemiplegic shoulder pain (HSP) as lower pain thresholds and higher rates of allodynia and hyperpathia have been demonstrated [101, 102].

The prevalence of shoulder pain following stroke was previously estimated to be 25–50% [4]. More recently, a retrospective study found a decreasing prevalence from 13% of

stroke rehabilitation inpatients in 2000 to 8% in 2015, which may be attributed in part to improvements in multidisciplinary acute care stroke units [103].

Clinical Assessment and Diagnosis Given the potential for multiple mechanisms contributing to HSP, with approximately one-third of HSP patients having two different shoulder pathologies, clinicians should conduct a thorough neuromusculoskeletal examination to evaluate for tone, strength, sensory changes, range of motion, joint alignment, and musculoskeletal pathologies [99, 104, 105]. If bony or soft tissue abnormalities in the shoulder are suspected, plain radiographs or ultrasound can be considered, respectively. The diagnosis of complex regional pain syndrome (CRPS) is based on the validated Budapest Criteria, but a triple phase bone scan can help exclude the disease [106, 107]. A diagnostic subacromial lidocaine injection test may assist in the differentiation between subacromial pathology and adhesive capsulitis [108].

Approach to the Treatment of Post-Stroke Shoulder Pain Treatment of post-stroke shoulder pain must be tailored based on clinical assessment and diagnoses. With pain and evidence of glenohumeral subluxation, the use of lap boards, arm troughs, shoulder orthoses, and neuromuscular electrical stimulation (NMES) should be considered. A recent systematic review found that shoulder orthoses reduce subluxation, but only while they are worn, and orthoses with both proximal and distal attachments were most effective [109]. Orthoses also improved pain, were well-tolerated, and did not increase the risk of contracture, spasticity, or hand edema [109]. No studies have tested whether immediate application of orthoses could prevent subluxation or pain, which represents a key question for future research [109]. Neuromuscular electrical stimulation (NMES) has been proposed to reduce subluxation by contracting and strengthening supraspinatus and posterior fibers of deltoid, which are important muscles for glenohumeral stabilization [110]. Two systematic reviews and meta-analyses reached similar conclusions: NMES was effective at reducing shoulder subluxation in the early post-stroke (less than 6 months), but not late post-stroke period, and did not improve shoulder pain or arm function [84, 111]. .Two randomized trials found that taping decreased shoulder pain but was ineffective in reducing subluxation [112, 113].

If the clinical examination of the patient with shoulder pain demonstrates spasticity, then strategies to manage spasticity should be employed (see "Spasticity" section above). Botulinum toxin can be injected into subscapularis and pectoralis major, which are the two most common spastic muscles implicated in HSP [114]. There are conflicting results from systematic reviews as to whether botulinum toxin injections help to improve post-stroke shoulder pain. A Cochrane systematic review found that a single intramuscular injection of botulinum toxin significantly reduced HSP at 3 and 6 months post-injection, though there were few studies and all were small [115]. A more recent systematic review and meta-analysis on the topic found a trend towards positive summary effect sizes for spasticity-related shoulder pain in the context of presumed insufficient statistical power [116]. There is a dearth of research into whether other spasticity interventions such as physiotherapy, pharmacotherapy, or phenol injections would be helpful for HSP.

Only a single small study...related to adhesive capsulitis. The investigators found that intraarticular steroid injection combined with hydrodilatation was better than conventional therapy or steroid injection alone in decreasing pain and improving shoulder range of motion and function [117]. The paucity of research in this common condition, implicated in one-half of post-stroke shoulder pain, is disappointing, and future studies should address this knowledge gap [105].

Treatment for post-stroke complex regional pain syndrome (CRPS) is better established in the literature, and includes early mobilization, mirror therapy, oral corticosteroids, stellate ganglion blockade, and psychological therapy [20, 114]. One small trial of 52 rehabilitation inpatients with subacute stroke and CRPS found that a 4-week upper extremity aerobic exercise program in combination with physiotherapy significantly improved pain and other symptoms of CRPS compared to physiotherapy alone [118]. A systematic review and meta-analysis of 38 studies concluded that adjunctive use of acupuncture with standard rehabilitation may be effective for improving pain, motor function, and performance of activities of daily living in patients with stroke [119]. Intravenous ketamine infusions were found to provide clinically meaningful pain relief of 3-month duration in patients with CRPS in a recent systematic review and meta-analysis, but no studies have specifically evaluated patients with post-stroke CRPS [120].

Finally, there is a limited but growing body of evidence for relatively new interventions in HSP. Bee venom interventions involve delivery via acupuncture needles or bee stingers to acupoints on the skin. Bee venom is thought to exert its therapeutic effects through anti-inflammatory, anti-apoptosis, and neuroprotective mechanisms [121]. A systematic review and meta-analysis of four small Korean trials suggested possible effectiveness of bee venom in treating post-stroke shoulder pain [122]. The suprascapular nerve has become another target for intervention in HSP because it receives sensory input from the shoulder joint and is implicated in sensitization related to chronic shoulder pain [123]. One randomized trial found that suprascapular nerve block significantly improved shoulder pain for up to 12 weeks compared to placebo injection [124], whereas two other trials demonstrated similar efficacy between suprascapular nerve block and intraarticular shoulder steroid injection in improving shoulder pain and passive range of motion [125, 126].

Recommendations for Future Research HSP is a common post-stroke pain syndrome and represents a challenge for both research scientists and clinicians. As it is known that multiple neurological and musculoskeletal pathologies can contribute to the broad diagnosis of HSP, we propose that improved differentiation of pain mechanisms, with associated accepted definitions (subluxation and adhesive capsulitis, for example, lack diagnostic criteria), are needed. The predominant underlying cause, or combination of causes, of HSP should be identified by thorough clinical assessment during study enrolment so that targeted interventions for subluxation-related pain, spasticity-related pain, and adhesive capsulitis-related pain can be better tailored to participants. In addition to small sample sizes, the heterogeneity of mechanisms for HSP in the existing literature may explain in part the conflicting and negative results in the existing literature on treatment of HSP.

Conclusions

Post-stroke pain is common and associated with impaired function and poorer quality of life in stroke survivors. However, its prevalence and natural history are understudied. Further, research focused on treatment of post-stroke pain is limited and the existing literature is frequently challenging to interpret due to methodological limitations. There is an urgent need for high-quality research on therapy for post-stroke pain (Table 1). In the interim, clinicians should actively inquire about pain in stroke survivors, even in those with a high level of functional independence, and should consider a multimodal approach to therapy incorporating lifestyle interventions in addition to pharmacological and non-pharmacological medical treatments.

Table 1 Suggestions to improve the methodological quality of research on post-stroke pain

Clarifying prevalence, risk factors, and prognosis

    Inclusion of pain as a secondary outcome in acute and secondary prevention stroke trials

    Use of common data elements for measurement of pain as well as potential contributing conditions (depression, fatigue, etc.)

Improving intervention studies

    Improved homogeneity of participants by stroke mechanism, pain syndromes

    Measurement and adjustment for potential demographic, clinical and psychosocial confounders

    Use of defined and accepted criteria for pain syndromes

    Large, multicenter randomized controlled trials, powered to detect clinically meaningful outcomes

    Prospective design with adequate longitudinal follow-up

    Minimization of loss to follow-up, cross-over

References

Papers of particular interest, published recently, have been highlighted as:
• Of importance
•• Of major importance

1. Feigin VL, Mensah GA, Norrving B, CJL M, Roth GA. GBD 2013 Stroke Panel Experts Group. Atlas of the Global Burden of Stroke (1990-2013): The GBD 2013 Study. Neuroepidemiology. 2015;45:230–6.

2. Campbell BCV, Majoie CBLM, Albers GW, Menon BK, Yassi N, Sharma G, et al. Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data. Lancet Neurol. 2019;18:46–55.

3. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723–31.

4. Harrison RA, Field TS. Post stroke pain: identification, assessment, and therapy. Cerebrovasc Dis. 2015;39:190–201.

5. Schopflocher D, Taenzer P, Jovey R. The prevalence of chronic pain in Canada. Pain Res Manag. 2011;16:445–50.

6. O'Donnell MJ, Diener H-C, Sacco RL, Panju AA, Vinisko R, Yusuf S, et al. Chronic pain syndromes after ischemic stroke: PRoFESS trial. Stroke. 2013;44:1238–43.

7. Lundström E, Smits A, Terént A, Borg J. Risk factors for stroke-related pain 1 year after first-ever stroke [Internet]. European Journal of Neurology. 2009:188–93. Available from: https://doi.org/10.1111/j.1468-1331.2008.02378.x.

8. Tang WK, Liang H, Mok V, Ungvari GS, Wong K-S. Is pain associated with suicidality in stroke? Arch Phys Med Rehabil. 2013;94:863–6.

9. Sommerfeld DK, Welmer A-K. Pain following stroke, initially and at 3 and 18 months after stroke, and its association with other disabilities. Eur J Neurol. 2012;19:1325–30.

10. Klit H, Finnerup NB, Jensen TS. Central post-stroke pain: clinical characteristics, pathophysiology, and management. Lancet Neurol. 2009;8:857–68.

11. Mitchell AJ, Sheth B, Gill J, Yadegarfar M, Stubbs B, Yadegarfar M, et al. Prevalence and predictors of post-stroke mood disorders:

A meta-analysis and meta-regression of depression, anxiety and adjustment disorder. Gen Hosp Psychiatry. 2017;47:48–60.

12. Shi Y, Yang D, Zeng Y, Wu W. Risk Factors for Post-stroke Depression: A Meta-analysis. Front Aging Neurosci. 2017;9:218.

13. Chen Y-K, Qu J-F, Xiao W-M, Li W-Y, Weng H-Y, Li W, et al. Poststroke fatigue: risk factors and its effect on functional status and health-related quality of life. Int J Stroke. Wiley Online Library. 2015;10:506–12.

14. Ezekiel L, Collett J, Mayo NE, Pang L, Field L, Dawes H. Factors Associated With Participation in Life Situations for Adults With Stroke: A Systematic Review. Arch Phys Med Rehabil. 2019;100:945–55.

15. Brunelli AA, Murphy GC, Athanasou JA. Effectiveness of Social Support Group Interventions for Psychosocial Outcomes: A Meta-analytic Review. The Australian Journal of Rehabilitation Counselling. Cambridge University Press. 2016;22:104–27.

16. Cano A, Williams AC de C. Social interaction in pain: reinforcing pain behaviors or building intimacy? Pain. 2010;149:9–11.

17.• Lai J, Harrison RA, Plecash A, Field TS. A Narrative Review of Persistent Post-Stroke Headache–A New Entry in the International Classification of Headache Disorders. Headache: The Journal of Head and Face Pain. Wiley Online Library. 2018;58:1442–53. **Here we consolidate knowledge to date on persistent post-stroke headache**.

18. Delpont B, Blanc C, Osseby GV, Hervieu-Bègue M, Giroud M, Béjot Y. Pain after stroke: A review. Rev Neurol. 2018;174:671–4.

19. Mulla SM, Wang L, Khokhar R, Izhar Z, Agarwal A, Couban R, et al. Management of Central Poststroke Pain: Systematic Review of Randomized Controlled Trials. Stroke. 2015;46:2853–60.

20. Treister AK, Hatch MN, Cramer SC, Chang EY. Demystifying Poststroke Pain: From Etiology to Treatment. PM R. Elsevier. 2017;9:63–75.

21. Saunders DH, Sanderson M, Hayes S, Kilrane M, Greig CA, Brazzelli M, et al. Physical fitness training for stroke patients [Internet]. Cochrane Database of Systematic Reviews. 2016. Available from. https://doi.org/10.1002/14651858.cd003316.pub6.

22.•• Saunders DH, Greig CA, Mead GE. Physical activity and exercise after stroke: review of multiple meaningful benefits. Stroke. 2014;45:3742–7. **This is a review of the evidence for the benefits for exercise after stroke, and how these align with patient, caregiver and clinician-defined priorities for stroke research**.

23. Devan H, Hale L, Hempel D, Saipe B, Perry MA. What Works and Does Not Work in a Self-Management Intervention for People With Chronic Pain? Qualitative Systematic Review and Meta-Synthesis. Phys Ther. 2018;98:381–97.

24. Kessler D, Egan M, Kubina L-A. Peer support for stroke survivors: a case study. BMC Health Serv Res. 2014;14:256.

25. Mallari B, Spaeth EK, Goh H, Boyd BS. Virtual reality as an analgesic for acute and chronic pain in adults: a systematic review and meta-analysis. J Pain Res. 2019;12:2053–85.

26. Laver KE, Lange B, George S, Deutsch JE, Saposnik G, Crotty M. Virtual reality for stroke rehabilitation. Cochrane Database Syst Rev. 2017;(11):CD008349.

27. Zou L, Sasaki JE, Zeng N, Wang C, Sun L. A Systematic Review With Meta-Analysis of Mindful Exercises on Rehabilitative Outcomes Among Poststroke Patients. Arch Phys Med Rehabil. 2018;99:2355–64.

28. Lawrence M, Celestino Junior FT, Matozinho HH, Govan L, Booth J, Beecher J. Yoga for stroke rehabilitation. Cochrane Database Syst Rev. 2017;(12):CD011483.

29. Almeida OP, Marsh K, Alfonso H, Flicker L, Davis TME, Hankey GJ. B-vitamins reduce the long-term risk of depression after stroke: the VITATOPS-DEP trial. Ann Neurol. Wiley Online Library. 2010;68:503–10.

30. Oh H, Seo W. A Comprehensive Review of Central Post-Stroke Pain. Pain Manag Nurs. 2015;16:804–18.

31. Staudt MD, Clark AJ, Gordon AS, Lynch ME, Morley-Forster PK, Nathan H, et al. Long-Term Outcomes in the Management of Central Neuropathic Pain Syndromes: A Prospective Observational Cohort Study. Can J Neurol Sci. 2018;45:545–52.

32. Vranken JH, Hollmann MW, van der Vegt MH, Kruis MR, Heesen M, Vos K, et al. Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial. Pain. 2011;152:267–73.

33. Kim JS, Bashford G, Murphy KT, Martin A, Dror V, Cheung R. Safety and efficacy of pregabalin in patients with central post-stroke pain [Internet]. Pain. 2011:1018–23. Available from:. https://doi.org/10.1016/j.pain.2010.12.023.

34. Lampl C, Schweiger C, Haider B, Lechner A. Pregabalin as mono- or add-on therapy for patients with refractory chronic neuropathic pain: a post-marketing prescription-event monitoring study [Internet]. Journal of Neurology. 2010:1265–73. Available from. https://doi.org/10.1007/s00415-010-5504-9.

35. Frese A, Husstedt IW, Ringelstein EB, Evers S. Pharmacologic treatment of central post-stroke pain. Clin J Pain. 2006;22:252–60.

36. Leijon G, Boivie J. Central post-stroke pain—a controlled trial of amitriptyline and carbamazepine. Pain. Elsevier. 1989;36:27–36.

37. Mulla SM, Buckley DN, Moulin DE, Couban R, Izhar Z, Agarwal A, et al. Management of chronic neuropathic pain: a protocol for a multiple treatment comparison meta-analysis of randomised controlled trials. BMJ Open. 2014;4:e006112.

38. Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013:CD006044.

39. Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014:CD005451.

40. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology. 2001;56:184–90.

41. Kumar B, Kalita J, Kumar G, Misra UK. Central Poststroke Pain: A Review of Pathophysiology and Treatment [Internet]. Anesthesia Analgesia. 2009:1645–57. Available from. https://doi.org/10.1213/ane.0b013e31819d644c.

42. Vick PG, Lamer TJ. Treatment of central post-stroke pain with oral ketamine [Internet]. Pain. 2001:311–3. Available from:. https://doi.org/10.1016/s0304-3959(00)00488-7.

43. Attal N, Gaudé V, Brasseur L, Dupuy M, Guirimand F, Parker F, et al. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology. 2000;54:564–74.

44. Batlle L, Mattie R, Irwin R. A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. PM R. 2016;8:278–81.

45. Pellicane AJ, Millis SR. Efficacy of methylprednisolone versus other pharmacologic interventions for the treatment of central post-stroke pain: a retrospective analysis. J Pain Res. 2013;6:557–63.

46. Aiyer R, Mehta N, Gungor S, Gulati A. A Systematic Review of NMDA Receptor Antagonists for Treatment of Neuropathic Pain in Clinical Practice. Clin J Pain. 2018;34:450–67.

47. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Pain, Palliative and Supportive Care Group, editor. Cochrane Database Syst Rev. 2013;(33):11.

48. Tanei T, Kajita Y, Noda H, Takebayashi S, Hirano M, Nakahara N, et al. Efficacy of tramadol/acetaminophen medication for central post-stroke pain. No Shinkei Geka. 2013;41:679–85.

49. McNicol ED, Ferguson MC, Schumann R. Methadone for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;(5): CD012499.

50. Henry JL, Lalloo C, Yashpal K. Central poststroke pain: an abstruse outcome. Pain Res Manag. 2008;13:41–9.

51. Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B, et al. Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology. 2017;42:1752–65.

52.• Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3:CD012182. **This is a recent systematic review and meta-analysis of the evidence for cannabinoids for neuropathic pain.**

53. Casale R, Symeonidou Z, Bartolo M. Topical Treatments for Localized Neuropathic Pain. Curr Pain Headache Rep. 2017;21: 15.

54.•• Hosomi K, Seymour B, Saitoh Y. Modulating the pain network—neurostimulation for central poststroke pain. Nat Rev Neurol. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 2015;11:290. **This is an excellent review of the proposed mechanisms by which neurostimulation may address post-stroke pain, and the evidence to date for pharmacological and neurostimulation specifically for central post-stroke pain.**

55. Kang N, Summers JJ, Cauraugh JH. Transcranial direct current stimulation facilitates motor learning post-stroke: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2016;87: 345–55.

56. Dionísio A, Duarte IC, Patrício M, Castelo-Branco M. The Use of Repetitive Transcranial Magnetic Stimulation for Stroke Rehabilitation: A Systematic Review. J Stroke Cerebrovasc Dis. 2018;27:1–31.

57. O'Connell NE, Marston L, Spencer S, DeSouza LH, Wand BM. Non-invasive brain stimulation techniques for chronic pain. Cochrane Database Syst Rev. 2018;(4):CD008208.

58. Velasco F, Argüelles C, Carrillo-Ruiz JD, Castro G, Velasco AL, Jiménez F, et al. Efficacy of motor cortex stimulation in the treatment of neuropathic pain: a randomized double-blind trial. J Neurosurg. 2008;108:698–706.

59. Lefaucheur J-P, Keravel Y, Nguyen J-P. Treatment of poststroke pain by epidural motor cortex stimulation with a new octopolar lead. Neurosurgery. 2011;68:180–7; discussion 187.

60. Mo J-J, Hu W-H, Zhang C, Wang X, Liu C, Zhao B-T, et al. Motor cortex stimulation: a systematic literature-based analysis of effectiveness and case series experience. BMC Neurol. 2019;19:48.

61. Lempka SF, Malone DA Jr, Hu B, Baker KB, Wyant A, Ozinga JG 4th, et al. Randomized clinical trial of deep brain stimulation for poststroke pain. Ann Neurol. 2017;81:653–63.

62. Tanei T, Kajita Y, Takebayashi S, Aoki K, Nakahara N, Wakabayashi T. Predictive Factors Associated with Pain Relief of Spinal Cord Stimulation for Central Post-stroke Pain. Neurol Med Chir. 2019;59:213–21.

63. Tanei T, Nakahara N, Takebayashi S. Dual lead spinal cord stimulation using octad lead for central post-stroke pain. No Shinkei Geka [Internet]. europepmc.org. 2012; Available from: https://europepmc.org/abstract/med/22466231.

64. Katayama Y, Yamamoto T, Kobayashi K, Kasai M, Oshima H, Fukaya C. Motor cortex stimulation for post-stroke pain: comparison of spinal cord and thalamic stimulation. Stereotact Funct Neurosurg. 2001;77:183–6.

65. Simpson BA. Spinal cord stimulation in 60 cases of intractable pain. J Neurol Neurosurg Psychiatry. 1991;54:196–9.

66. Yamamoto T, Watanabe M, Obuchi T, Kano T, Kobayashi K, Oshima H, et al. Importance of Pharmacological Evaluation in the Treatment of Poststroke Pain by Spinal Cord Stimulation. Neuromodulation. 2016;19:744–51.

67. Aly MM, Saitoh Y, Hosomi K, Oshino S, Kishima H, Yoshimine T. Spinal cord stimulation for central poststroke pain. Neurosurgery. 2010;67:ons206–12; discussion ons212.

68. Ramachandran VS, McGeoch PD, Williams L, Arcilla G. Rapid relief of thalamic pain syndrome induced by vestibular caloric stimulation. Neurocase. 2007;13:185–8.

69. McGeoch PD, Williams LE, Lee RR, Ramachandran VS. Behavioural evidence for vestibular stimulation as a treatment for central post-stroke pain. J Neurol Neurosurg Psychiatry. 2008;79:1298–301.

70. Spitoni GF, Pireddu G, Galati G, Sulpizio V, Paolucci S, Pizzamiglio L. Caloric Vestibular Stimulation Reduces Pain and Somatoparaphrenia in a Severe Chronic Central Post-Stroke Pain Patient: A Case Study. PLoS One. 2016;11:e0151213.

71. Cho S-Y, Park J-Y, Jung W-S, Moon S-K, Park J-M, Ko C-N, et al. Bee venom acupuncture point injection for central post stroke pain: a preliminary single-blind randomized controlled trial. Complement Ther Med. 2013;21:155–7.

72. Gibson W, Wand BM, O'Connell NE. Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;(9):CD011976.

73. Arnold M. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. boris.unibe.ch. 2018;38:1–211.

74. Hansen AP, Marcussen NS, Klit H, Kasch H, Jensen TS, Finnerup NB. Development of persistent headache following stroke: a 3-year follow-up. Cephalalgia. journals.sagepub.com. 2015;35: 399–409.

75. Hansen AP, Marcussen NS, Klit H, Andersen G, Finnerup NB, Jensen TS. Pain following stroke: a prospective study. Eur J Pain. 2012;16:1128–36.

76. Koopman K, Uyttenboogaart M, Vroomen PC, van der Meer J, De Keyser J, Luijckx G-J. Long-term sequelae after cerebral venous thrombosis in functionally independent patients. J Stroke Cerebrovasc Dis. 2009;18:198–202.

77. Schytz HW, Ashina M, Magyari M, Larsen VA, Olesen J, Iversen HK. Acute headache and persistent headache attributed to cervical artery dissection: Field testing of ICHD-III beta. Cephalalgia. 2014;34:712–6.

78. Ferro JM, Melo TP, Guerreiro M. Headaches in intracerebral hemorrhage survivors. Neurology. 1998;50:203–7.

79. Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, Mueller J. Early development of spasticity following stroke: a prospective, observational trial. J Neurol. 2010;257:1067–72.

80. Nam KE, Lim SH, Kim JS, Hong BY, Jung HY, Lee JK, et al. When does spasticity in the upper limb develop after a first stroke? A nationwide observational study on 861 stroke patients. J Clin Neurosci. 2019;66:144–8.

81. Katoozian L, Tahan N, Zoghi M, Bakhshayesh B. The Onset and Frequency of Spasticity After First Ever Stroke. J Natl Med Assoc. 2018;110:547–52.

82. Jin Y, Zhao Y. Post-stroke Upper Limb Spasticity Incidence for Different Cerebral Infarction Site. Open Med. 2018;13:227–31.

83. Tedesco Triccas L, Kennedy N, Smith T, Pomeroy V. Predictors of upper limb spasticity after stroke? A systematic review and meta-analysis. Physiotherapy. 2019;105:163–73.

84. Lee J-H, Baker LL, Johnson RE, Tilson JK. Effectiveness of neuromuscular electrical stimulation for management of shoulder subluxation post-stroke: a systematic review with meta-analysis. Clin Rehabil. journals.sagepub.com. 2017;31:1431–44.

85. Lannin NA, Herbert RD. Is hand splinting effective for adults following stroke? A systematic review and methodologic critique of published research. Clin Rehabil. 2003;17:807–16.

86. Andringa A, van de Port I, Meijer J-W. Long-term use of a static hand-wrist orthosis in chronic stroke patients: a pilot study. Stroke Res Treat. 2013;2013:546093.

87. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395–400.

88. Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008;89:799–806.

89. Wissel J, Ganapathy V, Ward AB, Borg J, Ertzgaard P, Herrmann C, et al. OnabotulinumtoxinA Improves Pain in Patients With Post-Stroke Spasticity: Findings From a Randomized, Double-Blind, Placebo-Controlled Trial. J Pain Symptom Manage. 2016;52:17–26.

90. Lindsay C, Kouzouna A, Simcox C, Pandyan AD. Pharmacological interventions other than botulinum toxin for spasticity after stroke. Cochrane Database Syst Rev. 2016;10: CD010362.

91. McCormick ZL, Chu SK, Binler D, Neudorf D, Mathur SN, Lee J, et al. Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life. PM R. 2016;8:553–62.

92. Creamer M, Cloud G, Kossmehl P, Yochelson M, Francisco GE, Ward AB, et al. Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. Stroke. 2018;49:2129–37.

93. Allan GM, Finley CR, Ton J, Perry D, Ramji J, Crawford K, et al. Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. Can Fam Physician. 2018;64:e78–94.

94. Marinelli L, Balestrino M, Mori L, Puce L, Rosa GM, Giorello L, et al. A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity. BMJ Open. 2017;7:e016843.

95. Chervyakov AV, Poydasheva AG, Lyukmanov RH, Suponeva NA, Chernikova LA, Piradov MA, et al. Effects of Navigated Repetitive Transcranial Magnetic Stimulation After Stroke. J Clin Neurophysiol. 2018;35:166–72.

96. Leo A, Naro A, Molonia F, Tomasello P, Saccà I, Bramanti A, et al. Spasticity Management: The Current State of Transcranial Neuromodulation. PM R. 2017;9:1020–9.

97. Huang Y-C, Liang P-J, Pong Y-P, Leong C-P, Tseng C-H. Physical findings and sonography of hemiplegic shoulder in patients after acute stroke during rehabilitation. J Rehabil Med. 2010;42:21–6.

98. Pong Y-P, Wang L-Y, Wang L, Leong C-P, Huang Y-C, Chen Y-K. Sonography of the shoulder in hemiplegic patients undergoing rehabilitation after a recent stroke. J Clin Ultrasound. 2009;37: 199–205.

99. Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, et al. Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. Am Heart Assoc. 2016;47:e98–169.

100. Rudd AG, Bowen A, Young GR, James MA. The latest national clinical guideline for stroke. Clin Med. 2017;17:154–5.

101. Soo Hoo J, Paul T, Chae J, Wilson RD. Central hypersensitivity in chronic hemiplegic shoulder pain. Am J Phys Med Rehabil. 2013;92:1–9; quiz 10–3.

102. Zeilig G, Rivel M, Weingarden H, Gaidoukov E, Defrin R. Hemiplegic shoulder pain: evidence of a neuropathic origin. Pain. 2013;154:263–71.

103. Menoux D, Jousse M, Quintaine V, Tlili L, Yelnik AP. Decrease in post-stroke spasticity and shoulder pain prevalence over the last 15 years. Ann Phys Rehabil Med [Internet]. Elsevier. 2018; Available from:. https://doi.org/10.1016/j.rehab.2018.03.003.

104. Hebert D, Lindsay MP, McIntyre A, Kirton A, Rumney PG, Bagg S, et al. Canadian stroke best practice recommendations: Stroke rehabilitation practice guidelines, update 2015. Int J Stroke. journals.sagepub.com. 2016;11:459–84.

105. Lo S-F, Chen S-Y, Lin H-C, Jim Y-F, Meng N-H, Kao M-J. Arthrographic and clinical findings in patients with hemiplegic shoulder pain. Arch Phys Med Rehabil. 2003;84:1786–91.

106. Harden RN, Bruehl S, Perez RSGM, Birklein F, Marinus J, Maihofner C, et al. Validation of proposed diagnostic criteria (the "Budapest Criteria") for Complex Regional Pain Syndrome. Pain. 2010;150:268–74.

107. Wertli MM, Brunner F, Steurer J, Held U. Usefulness of bone scintigraphy for the diagnosis of Complex Regional Pain Syndrome 1: A systematic review and Bayesian meta-analysis. PLoS One. 2017;12:e0173688.

108. Ewald A. Adhesive capsulitis: a review. Am Fam Physician. 2011;83:417–22.

109. Nadler M, Pauls M. Shoulder orthoses for the prevention and reduction of hemiplegic shoulder pain and subluxation: systematic review. Clin Rehabil. journals.sagepub.com. 2017;31:444–53.

110. Baker LL, Parker K. Neuromuscular electrical stimulation of the muscles surrounding the shoulder. Phys Ther. 1986;66:1930–7.

111. Vafadar AK, Côté JN, Archambault PS. Effectiveness of functional electrical stimulation in improving clinical outcomes in the upper arm following stroke: a systematic review and meta-analysis. Biomed Res Int. 2015;2015:729768.

112. Huang YC, Leong CP, Wang L, Wang LY, Yang YC, Chuang CY, et al. Effect of kinesiology taping on hemiplegic shoulder pain and functional outcomes in subacute stroke patients: a randomized controlled study. Eur J Phys Rehabil Med. 2016;52:774–81.

113. Chatterjee S, Hayner KA, Arumugam N, Goyal M, Midha D, Arora A, et al. The California Tri-pull Taping Method in the Treatment of Shoulder Subluxation After Stroke: A Randomized Clinical Trial. N Am J Med Sci. 2016;8:175–82.

114. Vasudevan JM, Browne BJ. Hemiplegic shoulder pain: an approach to diagnosis and management. Phys Med Rehabil Clin N Am. 2014;25:411–37.

115. Singh JA, Fitzgerald PM. Botulinum toxin for shoulder pain. Cochrane Database Syst Rev. cochranelibrary.com. 2010: CD008271.

116. Andringa A, van de Port I, van Wegen E, Ket J, Meskers C, Kwakkel G. Effectiveness of Botulinum Toxin Treatment for Upper Limb Spasticity Poststroke Over Different ICF Domains: a Systematic Review and Meta-Analysis [Internet]. Archives of Physical Medicine and Rehabilitation. 2019. Available from. https://doi.org/10.1016/j.apmr.2019.01.016.

117. Doğan A, Demirtaş R, Özgirgin N. Intraarticular hydraulic distension with steroids in the management of hemiplegic shoulder. Turkish Journal of Medical Sciences. The Scientific and Technological Research Council of Turkey. 2013;43:304–10.

118. Topcuoglu A, Gokkaya NKO, Ucan H, Karakuş D. The effect of upper-extremity aerobic exercise on complex regional pain syndrome type I: a randomized controlled study on subacute stroke. Top Stroke Rehabil. Taylor & Francis. 2015;22:253–61.

119. Liu S, Zhang CS, Cai Y, Guo X, Zhang AL, Xue CC, et al. Acupuncture for Post-stroke Shoulder-Hand Syndrome: A Systematic Review and Meta-Analysis. Front Neurol. frontiersin.org. 2019;10:433.

120. Zhao J, Wang Y, Wang D. The Effect of Ketamine Infusion in the Treatment of Complex Regional Pain Syndrome: a Systemic Review and Meta-analysis. Curr Pain Headache Rep. 2018;22:12.

121. Zhang S, Liu Y, Ye Y, Wang X-R, Lin L-T, Xiao L-Y, et al. Bee venom therapy: Potential mechanisms and therapeutic applications. Toxicon. 2018;148:64–73.

122. Lim SM, Lee S-H. Effectiveness of bee venom acupuncture in alleviating post-stroke shoulder pain: a systematic review and meta-analysis. J Integr Med. Elsevier. 2015;13:241–7.

123. Chang K-V, Hung C-Y, Wu W-T, Han D-S, Yang R-S, Lin C-P. Comparison of the Effectiveness of Suprascapular Nerve Block With Physical Therapy, Placebo, and Intra-Articular Injection in Management of Chronic Shoulder Pain: A Meta-Analysis of Randomized Controlled Trials. Arch Phys Med Rehabil. Elsevier. 2016;97:1366–80.

124. Adey-Wakeling Z, Crotty M, Shanahan EM. Suprascapular nerve block for shoulder pain in the first year after stroke: a randomized controlled trial. Stroke. 2013;44:3136–41.

125. Yasar E, Vural D, Safaz I, Balaban B, Yilmaz B, Goktepe AS, et al. Which treatment approach is better for hemiplegic shoulder pain in stroke patients: intra-articular steroid or suprascapular nerve block? A randomized controlled trial. Clin Rehabil. 2011;25:60–8.

126. Sencan S, Celenlioglu AE, Karadag-Saygı E, Midi İ, Gunduz OH. Effects of fluoroscopy-guided intraarticular injection, suprascapular nerve block, and combination therapy in hemiplegic shoulder pain: a prospective double-blind, randomized clinical study [Internet]. Neurological Sciences. 2019:939–46. Available from. https://doi.org/10.1007/s10072-019-03733-6.